Form 4: Lexicon Pharmaceuticals Director Judith L. Swain Reports Stock Option and Restricted Stock Unit Grant

Director Judith L. Swain reports the acquisition of stock options and restricted stock units in Lexicon Pharmaceuticals.

Summary

• On May 13, 2024, Judith L. Swain, a director of Lexicon Pharmaceuticals, reported the acquisition of 44,906 stock options with an exercise price of $1.79.
• These options vest in equal installments over three years from the grant date and expire on May 13, 2034.
• Swain also acquired 36,810 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock.
• These RSUs vest 100% on the first anniversary of the grant date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard compensation practices that align director interests with shareholders. There are no indications of negative events or concerns.

Positives

• The grant of stock options and RSUs to a director aligns their interests with those of the shareholders.
• The vesting schedules encourage long-term commitment and performance.

Industry Context

Stock option and RSU grants are common compensation practices for directors and executives in publicly traded companies, aligning their interests with shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the pharmaceutical industry, similar to companies like Amgen (AMGN) and Gilead Sciences (GILD).
• The vesting schedule of one-third annually for stock options is also typical, aligning with industry norms for long-term incentives.
• RSU grants are also common, providing a direct link to the company's stock performance, similar to compensation packages at Regeneron (REGN) and Vertex Pharmaceuticals (VRTX).

Stakeholder Impact

• Shareholders may view the grants positively as they incentivize the director to work towards increasing shareholder value.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates